Latest Lakefront Biotherapeutics News & Updates
See the latest news and media coverage for Lakefront Biotherapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing therapeutics for serious diseases
lakefrontbio.com- Headquarters
- Mechelen, Belgium
- Founded year
- 1999
- Company type
- Public company
- Number of employees
- 200–800
Last updated
Latest news about Lakefront Biotherapeutics
In short: Galapagos rebranded as Lakefront Biotherapeutics and exited its cell therapy business to focus on a strategic immunology partnership with Gilead.
Company announcements
-
Galapagos becomes Lakefront Biotherapeutics on May 8
Ticker changes from GLPG to LKFT. New LinkedIn page serves as primary update channel. Old page remains live during transition.
-
Galapagos reports Q1 2026 financial results
Announces Gilead collaboration on Ouro Medicines acquisition, name change to Lakefront Biotherapeutics, and €2B year-end cash outlook.
-
Galapagos shareholders adopt all board-proposed resolutions
The AGM approved reports, director remuneration, appointments including Henry Gosebruch as Executive Director, and auditor re-appointment. The EGM approved name change to Lakefront Biotherapeutics and share authorizations.
-
Galapagos enters binding agreement with Gilead
The collaboration advances gamgertamig, a T cell engager for autoimmune diseases, via Gilead's Ouro acquisition. Galapagos gains licenses, assets, and improved financial terms.
Media coverage
-
Lakefront Biotherapeutics NV (AMS:LKFT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Lakefront Biotherapeutics NV ( AMS:LKFT ) last week reported its latest quarterly results, which makes it a good ...
-
Lakefront Biotherapeutics Sponsored ADR
View Lakefront Biotherapeutics Sponsored ADR LKFT stock quote prices, financial information, real-time forecasts, and company news from CNN.
-
Galapagos Rebrands as Lakefront Biotherapeutics and Reshapes Portfolio Around Gilead–Ouro Autoimmune Deal
On May 6, 2026, Galapagos reported first-quarter 2026 results and detailed a strategic pivot centered on a binding collaboration with Gilead Sciences tied to Gilead’s...
-
Earnings call transcript: Galapagos Q1 2026 beats EPS, revenue falls short By Investing.com
Galapagos NV reported its Q1 2026 earnings, revealing a significant EPS beat but a substantial...
Track Lakefront Biotherapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Lakefront Biotherapeutics competitors & trending companies
Browse news for competitors to Lakefront Biotherapeutics and other trending companies.
Abcuro
Bambusa
NewLimit
Biogen
Retro
Novartis
Mirum Pharmaceuticals
BMS
Annexon Biosciences
Ionis
Alligator Bioscience
Structure Therapeutics
Precigen
Neurimmune
MediciNova
Tiziana Life Sciences
Sironax
Insmed
Vertex
Xintela
Herantis Pharma
BioInvent
NeuroSense Therapeutics
Dunad Therapeutics
Nektar
Agomab Therapeutics
Repertoire Immune Medicines
Orna Therapeutics
Mesoblast
Immutep
Amgen
Incyte
Regeneron
Applied Digital
QS
Silex